Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Luqa Pharma Approved to Market Adare Diarrhea Treatment in China

publication date: Oct 15, 2019

Luqa Pharma, a Shanghai specialty in-licensing pharma, together with Adare Pharma of France, announced that Lactéol®, a microbiome treatment for diarrhea, was approved for China use. Lactéol ® is a proprietary combination of Lactobacillus LB (Lactobacillus fermentum and Lactobacillus delbrueckii) and neutralized fermented culture medium. An oral prescription drug, it will be available in sachets in China hospitals. Founded in 2010, Luqa has built a portfolio of products for wound healing, acne, scar treatments, fungal infections, gastrointestinal and aesthetic products, which it markets in greater China. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital